![Polygenic Risk Scores: A Cardiovascular Conundrum](https://www.g2intelligence.com/wp-content/uploads/2023/12/Jan24.CDI_.CVDScreening.MS-iStock-492192012_1100x800-1-1080x675.jpg)
Polygenic Risk Scores: A Cardiovascular Conundrum
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?
Diana W. Bianchi, MD, discusses how NIPT has evolved, key challenges, as well as her team’s research on using these tests to detect cancer.
Genomic sequencing is almost twice as likely to yield a diagnostic result, but lags behind panel testing in speed, cost, and concordance.
Recent cases involve charges and judgments related to COVID-19 add-on tests, genetic testing fraud, and kickbacks.
A strategic partnership with Google enables more accurate whole genome sequencing with machine learning.